Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vanda Pharmaceuticals (VNDA) Cash from Financing Activities: 2010-2025

Historic Cash from Financing Activities for Vanda Pharmaceuticals (VNDA) over the last 11 years, with Sep 2025 value amounting to -$517,000.

  • Vanda Pharmaceuticals' Cash from Financing Activities was N/A to -$517,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.4 million, marking a year-over-year change of. This contributed to the annual value of -$155,000 for FY2024, which is N/A change from last year.
  • Latest data reveals that Vanda Pharmaceuticals reported Cash from Financing Activities of -$517,000 as of Q3 2025, which was down 21.65% from -$425,000 recorded in Q2 2025.
  • In the past 5 years, Vanda Pharmaceuticals' Cash from Financing Activities registered a high of $1.8 million during Q1 2021, and its lowest value of -$1.3 million during Q1 2025.
  • Over the past 2 years, Vanda Pharmaceuticals' median Cash from Financing Activities value was -$471,000 (recorded in 2025), while the average stood at -$605,250.
  • In the last 5 years, Vanda Pharmaceuticals' Cash from Financing Activities spiked by 286.01% in 2021 and then plummeted by 98.92% in 2022.
  • Quarterly analysis of 4 years shows Vanda Pharmaceuticals' Cash from Financing Activities stood at $1.0 million in 2021, then slumped by 41.88% to $605,000 in 2022, then reached -$155,000 in 2024, then reached -$517,000 in 2025.
  • Its Cash from Financing Activities was -$517,000 in Q3 2025, compared to -$425,000 in Q2 2025 and -$1.3 million in Q1 2025.